Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Cerilliant
Cantor Fitzgerald
Dow
Boehringer Ingelheim
US Army
Medtronic
McKinsey
Johnson and Johnson

Generated: September 23, 2018

DrugPatentWatch Database Preview

GEODON Drug Profile

« Back to Dashboard

When do Geodon patents expire, and when can generic versions of Geodon launch?

Geodon is a drug marketed by Pfizer and Pfizer Inc and is included in three NDAs. There are three patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in GEODON is ziprasidone mesylate. There are twenty-one drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the ziprasidone mesylate profile page.

Drug patent expirations by year for GEODON
Pharmacology for GEODON
Synonyms for GEODON
122883-93-6,138982-67-9(ClH.H2O),146939-27-7(freebase)
138982-67-9 (hydrochloride monohydrate)
146939-27-7
2H-Indol-2-one, 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-
2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-
4169AH
4770-EP2272537A2
4770-EP2272841A1
4770-EP2275420A1
4770-EP2280010A2
4770-EP2298731A1
4770-EP2298776A1
4770-EP2301936A1
4770-EP2308875A1
4770-EP2316836A1
5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one
5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2H-indole-2-one
5-(2-(4-(benzo[d]isothiazol-3-yl)piperazin-1-yl)ethyl)-6-chloroindolin-2-one
5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-6-chloro-1,3-dihydro-indol-2-one
5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-6-chloro-1,3-dihydro-indol-2-one (Ziprasidone)
5-[2-(4-Benzo[d]isothiazol-3-yl-piperazin-1-yl)-ethyl]-6-chloro-1,3-dihydro-indol-2-one(Norastemizole)
5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one
5-[2-[4-(1,2-benzothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydroindol-2-one
5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-6-chloranyl-1,3-dihydroindol-2-one
5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-6-chloro-1,3-dihydroindol-2-one
5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-6-chloro-indolin-2-one
5-{2-[4-(1,2-benzisothiazol-3-yl)piperazin-1-yl]ethyl}-6-chloro-1,3-dihydro-2H-indol-2-one
5-{2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl}-6-chloro-1,3-dihydro-2H-indol-2-one
5-{2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl}-6-chloro-2,3-dihydro-1H-indol-2-one
6-chloro-5-[2-[4-(7-thia-8-azabicyclo[4.3.0]nona-1,3,5,8-tetraen-9-yl)piperazin-1-yl]ethyl]-1,3-dihydroindol-2-one
6UKA5VEJ6X
883Z936
A808568
AB00639925_05
AB00639925_06
AB00639925-02
AB00639925-04
AC-23360
AC1L1U27
AJ-23401
AKOS015900383
AM90310
Ambap122883-93-6
AN-16930
API0004647
BC643069
BDBM50048803
BIDD:GT0042
C07568
C21H21ClN4OS
CAS-146939-27-7
CHEBI:10119
CHEMBL708
CP 88059
CP 88059-01
CP 88059;CP-88059;CP88059
CP-88,059
CP-88,059-01
CP-88,059-1
CP-88059-1
CP-88059-27
CP-880591
CP-8805927
CPD000466328
CS-1071
CZ0013
D08687
D0E0NJ
D0R1JV
DB00246
DSSTox_CID_3753
DSSTox_GSID_23753
DSSTox_RID_77186
DTXSID4023753
FT-0654208
FT-0655916
Geodon (TN)
Geodon Oral
GTPL59
HSDB 7745
HY-14542
I14-0766
L000659
LS-83744
MLS000759435
MolPort-003-850-885
MVWVFYHBGMAFLY-UHFFFAOYSA-N
NCGC00186050-01
NCGC00263539-01
NCGC00263539-03
SAM001246607
SC-22049
SCHEMBL28028
SMR000466328
TC-5280
TL8000889
Tox21_112194
Tox21_112194_1
Tox21_113525
UNII-6UKA5VEJ6X
VU0286234-2
W-5149
zaprasidone
Zeldox
Zeldox (TN)
ZINC538550
Zipradon
Zipradon (TN)
ziprasidona
Ziprasidone
Ziprasidone (INN)
Ziprasidone [INN:BAN]
Ziprasidone hydrochloride
Ziprasidone mesilate
Ziprasidone mesylate
Ziprasidone mesylate trihydrate
Ziprasidone solution, 1.0 mg/mL in 1,2-dimethoxyethane, ampule of 1 mL, certified reference material
ziprasidonum
ziprazidone

US Patents and Regulatory Information for GEODON

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer GEODON ziprasidone hydrochloride CAPSULE;ORAL 020825-001 Feb 5, 2001 AB RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Pfizer GEODON ziprasidone hydrochloride CAPSULE;ORAL 020825-004 Feb 5, 2001 AB RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Pfizer GEODON ziprasidone hydrochloride CAPSULE;ORAL 020825-002 Feb 5, 2001 AB RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Pfizer Inc GEODON ziprasidone hydrochloride SUSPENSION;ORAL 021483-001 Mar 29, 2006 DISCN No No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Pfizer GEODON ziprasidone hydrochloride CAPSULE;ORAL 020825-004 Feb 5, 2001 AB RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Pfizer GEODON ziprasidone hydrochloride CAPSULE;ORAL 020825-001 Feb 5, 2001 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Pfizer GEODON ziprasidone hydrochloride CAPSULE;ORAL 020825-002 Feb 5, 2001 AB RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for GEODON

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pfizer GEODON ziprasidone mesylate INJECTABLE;INTRAMUSCULAR 020919-001 Jun 21, 2002 ➤ Sign Up ➤ Sign Up
Pfizer GEODON ziprasidone hydrochloride CAPSULE;ORAL 020825-001 Feb 5, 2001 ➤ Sign Up ➤ Sign Up
Pfizer GEODON ziprasidone hydrochloride CAPSULE;ORAL 020825-002 Feb 5, 2001 ➤ Sign Up ➤ Sign Up
Pfizer Inc GEODON ziprasidone hydrochloride SUSPENSION;ORAL 021483-001 Mar 29, 2006 ➤ Sign Up ➤ Sign Up
Pfizer GEODON ziprasidone mesylate INJECTABLE;INTRAMUSCULAR 020919-001 Jun 21, 2002 ➤ Sign Up ➤ Sign Up
Pfizer GEODON ziprasidone mesylate INJECTABLE;INTRAMUSCULAR 020919-001 Jun 21, 2002 ➤ Sign Up ➤ Sign Up
Pfizer GEODON ziprasidone mesylate INJECTABLE;INTRAMUSCULAR 020919-001 Jun 21, 2002 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for GEODON
Drugname Dosage Strength RLD Date
➤ Subscribe Capsules 20 mg, 40 mg, 60 mg and 80 mg ➤ Subscribe ➤ Sign Up

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Cerilliant
Cantor Fitzgerald
Dow
Boehringer Ingelheim
US Army
Medtronic
McKinsey
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.